$5.70
-0.17 (-2.90%)
Maxygen, Inc. (MAXY)
CAPS Rating:
A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

RSS Headlines
Fool UK
Recs
Despite having a decent cash position the company has decided to defer further development of Maxy-G34 until a partner is found to fund it. Given that this is their only program in clinical development, it's difficult to see where things go from here. I know that Neose's GCSF analogue didn't attract a partner and that stock is trading in pennies.